Heterogeneity of mucosal mast cell infiltration in subgroups of patients with esophageal chest pain

Neurogastroenterology and Motility

Volumn 26, Issue 6, 2014, Pages 786-793

  Lee, H ^a   Chung, H ^a   Park, J C ^a   Shin, S K ^a   lee, S K ^a   Lee, Y C ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Mast cell; Non cardiac chest pain; Overlap

Indexed keywords

ADULT; AGED; ARTICLE; CELL COUNT; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; ESOPHAGEAL CHEST PAIN; ESOPHAGEAL PH MONITORING; ESOPHAGUS MUCOSA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; MAST CELL; PAIN ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; THORAX PAIN; CHEST PAIN; COMPLICATION; CYTOLOGY; ESOPHAGUS; ESOPHAGUS DISEASE; INTESTINE MUCOSA; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADULT; AGED; CELL COUNT; CHEST PAIN; ESOPHAGEAL DISEASES; ESOPHAGUS; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MAST CELLS; MIDDLE AGED; YOUNG ADULT;

EID: 84901473450     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12325     Document Type: Article

References (32)

1. Fass R, Dickman R. Non-cardiac chest pain: an update. Neurogastroenterol Motil 2006; 18: 408-17.
2. Eslick GD, Talley NJ. Non-cardiac chest pain: predictors of health care seeking, the types of health care professional consulted, work absenteeism and interruption of daily activities. Aliment Pharmacol Ther 2004; 20: 909-15.
3. Fass R, Achem SR. Noncardiac chest pain: epidemiology, natural course and pathogenesis. J Neurogastroenterol Motil 2011; 17: 110-23.
4. Barbara G, Stanghellini V, De Giorgio R, Corinaldesi R. Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil 2006; 18: 6-17.
5. Farre R, Fornari F, Blondeau K, Vieth M, De Vos R, Bisschops R, Mertens V, Pauwels A et al. Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus. Gut 2010; 59: 164-9.
6. Woodland P, Al-Zinaty M, Yazaki E, Sifrim D. In vivo evaluation of acid-induced changes in oesophageal mucosa integrity and sensitivity in non-erosive reflux disease. Gut 2013; 62: 1256-61.
7. Farre R. Pathophysiology of gastro-esophageal reflux disease: a role for mucosa integrity? Neurogastroenterol Motil 2013; 25: 783-99.
8. Kirsch R, Bokhary R, Marcon MA, Cutz E. Activated mucosal mast cells differentiate eosinophilic (allergic) esophagitis from gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007; 44: 20-6.
9. Jung HK, Halder S, McNally M, Locke GR 3rd, Schleck CD, Zinsmeister AR, Talley NJ. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Ther 2007; 26: 453-61.
10. Talley NJ. Functional (non-ulcer) dyspepsia and gastroesophageal reflux disease: one not two diseases? Am J Gastroenterol 2013; 108: 775-7.
11. Savarino E, Pohl D, Zentilin P, Dulbecco P, Sammito G, Sconfienza L, Vigneri S, Camerini G et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 2009; 58: 1185-91.
12. Quigley EM. Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities? Best Pract Res Clin Gastroenterol 2004; 18: 695-706.
13. Gasiorowska A, Poh CH, Fass R. Gastroesophageal reflux disease (GERD) and irritable bowel syndrome (IBS)-is it one disease or an overlap of two disorders? Dig Dis Sci 2009; 54: 1829-34.
14. Fass R, Ofman JJ, Sampliner RE, Camargo L, Wendel C, Fennerty MB. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther 2000; 14: 389-96.
15. O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O'Morain CA. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000; 12: 449-57.
16. Park JH, Rhee PL, Kim HS, Lee JH, Kim YH, Kim JJ, Rhee JC. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 2006; 21: 71-8.
17. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
18. Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut 2011; 60: 1473-8.
19. Anand P, Aziz Q, Willert R, van Oudenhove L. Peripheral and central mechanisms of visceral sensitization in man. Neurogastroenterol Motil 2007; 19: 29-46.
20. Woodland P, Lee C, Duraysami Y, Farre R, Dettmar P, Sifrim D. Assessment and protection of esophageal mucosal integrity in patients with heartburn without esophagitis. Am J Gastroenterol 2013; 108: 535-43.
21. Woodland P, Sifrim D. Esophageal mucosal integrity in nonerosive reflux disease. J Clin Gastroenterol 2014; 48: 6-12.
22. Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am 2005; 34: 235-45, vi-vii.
23. Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, Trevisani M, Campi B et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132: 26-37.
24. Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E, Ardid D. Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 2012; 36: 1009-31.
25. Vanheel H, Vicario M, Vanuytsel T, Van Oudenhove L, Martinez C, Keita ÅV, Pardon N, Santos J et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut 2014; 63: 262-71.
26. Walker MM, Talley NJ, Prabhakar M, Pennaneac'h CJ, Aro P, Ronkainen J, Storskrubb T, Harmsen WS, Zinsmeister AR et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2009; 29: 765-73.
27. Farmer AD, Coen SJ, Kano M, Naqvi H, Paine PA, Scott SM, Furlong PL, Lightman SL et al. Psychophysiological responses to visceral and somatic pain in functional chest pain identify clinically relevant pain clusters. Neurogastroenterol Motil 2014; 26: 139-48.
28. Dickman R, Feroze H, Fass R. Gastroesophageal reflux disease and irritable bowel syndrome: a common overlap syndrome. Curr Gastroenterol Rep 2006; 8: 261-5.
29. Kaji M, Fujiwara Y, Shiba M, Kohata Y, Yamagami H, Tanigawa T, Watanabe K, Watanabe T et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol 2010; 25: 1151-6.
30. Mudipalli RS, Remes-Troche JM, Andersen L, Rao SS. Functional chest pain: esophageal or overlapping functional disorder. J Clin Gastroenterol 2007; 41: 264-9.
31. Serna H, Porras M, Vergara P. Mast cell stabilizer ketotifen [4-(1-methyl-4-piperidylidene)-4 h-benzo[4, 5]cyclohepta[1, 2-b]thiophen-10(9H)-one fumarate] prevents mucosal mast cell hyperplasia and intestinal dysmotility in experimental Trichinella spiralis inflammation in the rat. J Pharmacol Exp Ther 2006; 319: 1104-11.
32. Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, Schemann M, Bischoff SC et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010; 59: 1213-21.